Retatrutide is an investigational once-weekly injectable peptide being developed by Eli Lilly and Company. It is unique as a "triple agonist" that activates three key hormone receptors: GLP-1 (reduces appetite and slows stomach emptying), GIP (improves insulin response), and Glucagon (increases energy expenditure and lipid catabolism). This multi-pathway mechanism is designed to produce exceptional metabolic regulation and weight-loss outcomes in experimental research models.
| Scientific name | Retatrutide Acetate |
|---|---|
| CAS number | 2381015-81-2 |
| Molecular formula | C221H342N46O68 |
| Molecular weight | 4731.33 g/mol |
| Sequence | Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2 |
| Form | Lyophilized Powder |
| HPLC purity | 99.7% |
Store lyophilized powder at -20°C for up to 2 years. Keep away from ambient humidity and direct sunlight. Once reconstituted, store at 2°C to 8°C (refrigerated) and utilize within 14 days.
Add 2.0 mL of Sterile Bacteriostatic Water slowly down the side of the vial. Do not spray directly. Swirl in a circular motion until completely dissolved into a clear, colorless liquid.
Certificate of Analysis (COA) for Retatrutide
Free tracked EU shipping — received within 10 working days. Lost or damaged parcels are replaced free of charge. 30-day refund policy.
For laboratory research use only. Products are not approved by the FDA or EMA for human or veterinary use, and are not drugs, dietary supplements or cosmetics.
